Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03654313 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
A Phase 1 study of Cardiovascular Disease and Atherosclerosis, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
- 9
- Study locations
NCT03654313 is a Phase 1 study of Cardiovascular Disease and Atherosclerosis that has completed, run by MedImmune. The registered enrollment target is 88 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT03654313, a Phase 1 study of Cardiovascular Disease and Atherosclerosis, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
- 9
- Study locations
Study Summary
To evaluate the safety, tolerability, PK and immunogenicity of single and multiple ascending doses of MEDI6570 in subjects with Type 2 Diabetes Mellitus
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MEDI6570
- BIOLOGICAL Part B Placebo
Study Locations (9)
Florida
- Research Site - Jacksonville
- Research Site - Miami
- Research Site - Port Orange
Alabama
- Research Site - Anniston
Hawaii
- Research Site - Honolulu
North Carolina
- Research Site - High Point
Ohio
- Research Site - Cincinnati
Tennessee
- Research Site - Knoxville
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2020-07-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03654313
The ClinicalTrials.gov registry entry for NCT03654313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (97% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03654313 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, Alabama, Hawaii.
Frequently Asked Questions
What is clinical trial NCT03654313 about?
NCT03654313 is a clinical study titled "Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus". To evaluate the safety, tolerability, PK and immunogenicity of single and multiple ascending doses of MEDI6570 in subjects with Type 2 Diabetes Mellitus
What is the current status of trial NCT03654313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2018-09-28. Estimated completion is 2020-07-21.
What conditions does trial NCT03654313 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Atherosclerosis.
What interventions are being tested in trial NCT03654313?
The interventions under investigation include: Placebo (BIOLOGICAL), MEDI6570 (BIOLOGICAL), Part B Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT03654313?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03654313 being conducted?
This trial has 9 study locations across Alabama, Florida, Hawaii, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
RECRUITING · Phase 1
-
A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
COMPLETED · Phase 1
-
Fructose-Induced Palmitate Synthesis in Overweight Subjects
COMPLETED · Phase 1
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
COMPLETED · Phase 1
-
Single-tracer Multiparametric PET Imaging
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.